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Abstract.	 A	 series	 of	 highly	 substituted	 tetrahydrofurans	 (THFs),	 decorated	 with	 modifiable	 2-aryl,	 3-
carboxy	and	4-amino	substituents,	has	been	prepared	 for	biological	evaluation	within	the	European	Lead	
Factory.	 Diastereoselective	 reductive	 amination	 of	 pre-functionalised	 4-oxofurans,	 readily	 prepared	 from	
cinnamate	esters	via	oxa-Michael/Dieckmann	annulation,	provided	the	requisite	THF	cores	on	gram	scale	
with	three	contiguous	stereocentres,	including	full	substitution	at	C-3.	In	a	second	series,	a	pyrrolidine	ring	
was	 fused	 to	 the	 same	 oxofuran	 scaffold	 via	 an	 intramolecular	 reductive	 amination,	 inverting	 the	
configuration	 at	 C-4	 relative	 to	 the	 other	 ring	 substituents.	 The	 resulting	 compounds,	 which	 displayed	
desirable	physical	properties	as	lead-like	scaffolds,	were	derivatised	into	a	small	 library	of	24	compounds,	
demonstrating	their	ability	to	serve	as	starting	points	for	drug	discovery.	Ultimately,	this	chemistry	enabled	
the	preparation	of	1948	THF-containing	compounds	for	inclusion	in	the	Joint	European	Compound	Library.			
	
Introduction	
The	 search	 for	 new	 bioactive	 small	 molecules	 lies	 at	 the	 heart	 of	 modern	 drug	 discovery	
programmes.	 	 In	 addition,	 such	 molecules	 serve	 as	 useful	 probes	 for,	 and	 modulators	 of,	 the	
activity	 of	 a	 range	 of	 proteins.	 In	 the	 quest	 for	 these	 high	 value	 small	 molecules	 as	 potential	
medicines	or	biological	tools,[1‒3]	natural	products	often	play	a	key	role.	For	example,	in	the	30	years	
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to	2010,	an	estimated	26%	of	new	medicines	were	either	natural	products	or	derivatives	thereof,	
with	a	further	13%	possessing	a	natural	product-like	pharmacophore.[4]	Natural	products	have	also	
inspired	 a	 number	 of	 approaches	 to	 replicate	 the	 key	 structural	 features	 of	 these	 often	 densely	
functionalised	 small	bioactive	molecules,	 and	 this	has	been	aided	by	analysis	 and	 charting	of	 the	
chemical	 space	 populated	 by	 medicinally	 active	 natural	 products.[5,6]	 In	 attempting	 to	 define	
“natural	 product	 likeness”	 the	 analysis	 identified	 oxygen-containing	 heterocycles	 as	 a	 major	
contributor	to	chemical	space	for	drug	discovery.[5,6]	
Within	 the	 large	 family	 of	 oxygen	 heterocycle-containing	 natural	 products	 that	 occupy	
biologically	relevant	chemical	space,[5]	the	tetrahydrofuran	(THF)	ring	system	assumes	an	important	
place.	 It	 is	 found	 in	 myriad	 natural	 products,[7]	 biologically	 active	 small	 molecules[8]	 and	 FDA-
approved	drugs.[9]	 The	 significance	of	 the	THF	moiety	 in	medicinal	 chemistry	 continues	 to	 inspire	
the	 development	 of	 methods	 for	 the	 de	 novo	 synthesis	 of	 functionalised	 variants	 and	 THF-
containing	natural	products,[10,11]	as	well	as	methods	for	selective	C‒H	functionalisation	of	the	ring	
itself.[12]			
	
	
Figure	1.	Exemplar	amino-substituted	THFs	with	biological	activity.[15‒17]	
	
As	part	of	our	contributions[13]	to	the	European	Lead	Factory	(ELF)	drug	discovery	initiative,[14]	we	
were	interested	in	the	design	and	synthesis	of	new	THF	scaffolds	bearing	an	amino	substituent	on	
the	heterocycle	backbone	(i.e.,	at	C-3	or	C-4).	 In	addition	to	serving	as	a	convenient	 template	 for	
library	 synthesis,	 the	biological	 activity	of	 amino-THFs	 is	well	 precedented	 (e.g.,	 compounds	1‒3,	
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Figure	 1).[15‒17]	 In	 the	 design	 of	 a	 lead-like	 scaffold[18]	 incorporating	 this	 structural	 feature	 that	
fulfilled	the	requirements	of	the	ELF,[14]	we	 identified	THF	4	as	our	principal	target	(Scheme	1).	 In	
addition	 to	 the	 key	 amino	group	at	C-4,	 a	 carboxylic	 acid	or	derived	 functionality	 (e.g.,	 amide	or	
hydroxymethyl)	 was	 proposed	 at	 C-3	 as	 a	 second	 major	 point	 for	 orthogonal	 diversification.	
Notably,	 despite	 the	 intense	 general	 interest	 in	 THF-based	 amino	 acids,[19]	 THFs	 containing	 an	
embedded	 β-amino	 acid	 (or	 derivative)	 of	 equivalent	 constitution	 to	 compound	 4	 remain	
underrepresented	 in	 the	 literature.[20]	 To	 complete	 our	 scaffold	 design,	 an	 aryl	 group	 was	
incorporated	 at	 C-2	 to	 increase	 the	 lead-likeness,[21]	 stereochemical	 complexity[22]	 and	 diversity	
potential	of	the	scaffold.		
Given	that	THF	4	is	a	purely	synthetic	scaffold	intended	for	high-throughput	screening,	we	did	not	
target	a	specific	stereoisomer	at	the	outset.	However,	to	ensure	synthetic	tractability,	it	remained	
of	 prime	 importance	 to	 establish	 a	 synthetic	 pathway	 capable	 of	 controlling	 the	 relative	
stereochemistry	at	three	contiguous	centres	(C-2,	C-3,	C-4)	with	high	fidelity,	in	favour	of	one	of	the	
four	 possible	 diastereomers.	 To	 gain	 access	 to	 our	 primary	 target,	 we	 envisioned	 a	 reductive	
amination	 using	 4-oxofuran	 5,	 which	 itself	 could	 arise	 from	 a	 tandem	 oxa-Michael/Dieckmann	
condensation	 using	 readily	 available	 starting	 materials,	 namely	 glycolate	 6	 and	 cinnamate	 7	
(Scheme	1).	The	β-keto	ester	functionality	embedded	in	4-oxofuran	5	was	also	expected	to	endow	
flexibility	to	produce	C-3	fully-substituted	derivatives	via	alkylation,[23]	 including	introduction	of	an	
aminoethyl	 tether,	 allowing	 reductive	 cyclisation	 to	 give	 our	 second	 THF-containing	 target	 -	 the	
pyrrolidino-fused	bicycle	8,	thereby	creating	molecular	complexity	from	simple	starting	materials	in	
a	few	steps.	
	
	
Scheme	1.	General	synthetic	strategy	to	target	THF	scaffolds.		
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Results	and	Discussion	
The	oxa-Michael/Dieckmann	 annulation	 of	 the	 type	 shown	 in	 Scheme	1	 is	well	 established	using	
acrylate	esters	or	β-alkyl-acrylate	esters	as	Michael	acceptors,[24[	but	there	is	little	precedent	for	the	
use	of	 less	 electrophilic	 cinnamate	esters[25]	 in	 such	a	process	 to	provide	an	aryl	 group	at	C-2.[26]	
After	considerable	optimisation	(base/solvent/temperature/time/R	group	in	Scheme	2),	we	arrived	
at	 a	 practical	 procedure	 to	 obtain	 the	 required	 oxo-furans	 9	 and	 10	 on	 decagram	 scales	 in	
reasonable	yields	(Scheme	2).	Our	choice	to	prepare	the	meta-methoxy	derivative	10	was	based	on	
the	installation	of	an	activating/directing	group	to	enable	potential	late-stage	electrophilic	aromatic	
substitution,	while	 avoiding	 compromising	 the	 stability	 of	 the	 embedded	benzylic	 ether	 in	 THF	4	
through	mesomeric	effects.	During	reaction	optimisation,	a	mixed	ester	reactant	combination[24b]	of	
tert-butyl	cinnamate	and	methyl	glycolate	was	also	investigated,	which	gave	a	low	yield	of	THF	11	
(20%)	amidst	complications	from	partial	product	transesterification	to	methyl	ester	9	 (Scheme	2).	
Nonetheless,	 an	 X-ray	 structure	 of	 the	 crystalline	 tert-butyl	 ester	 11	 enabled	 assignment	 of	 the	
trans	stereochemistry	to	all	annulation	products	by	comparison	of	the	JH2‒H3	coupling	constant	(10.2	
Hz	for	compounds	9‒11).	
	
	
Scheme	2.	Synthesis	of	key	intermediates	9	and	10	and	attempted	elaboration	of	9	to	β-amino	ester	14.	
	
Installation	 of	 the	 requisite	 C-4-amino	 group	 was	 investigated	 via	 stepwise	 formation	 of	 a	 β-
enamino	ester	 and	 subsequent	 reduction	 (Scheme	2).	Our	 initial	 attempt	 to	prepare	an	enamine	
from	β-ketoester	 9	 was	 carried	 out	 with	 ammonium	 acetate	 in	methanol,	 giving	 a	 19%	 yield	 of	
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enamine	12	 due	 to	predominant	C-3‒C-4	bond	 cleavage	by	methanol-mediated	 retro-Dieckmann	
reaction	(Scheme	S1,	SI).	This	competing	side	reaction	was	completely	suppressed	by	switching	to	
the	 less	 nucleophilic	 trifluoroethanol	 as	 solvent,	 giving	 a	 quantitative	 yield	 of	 enamine	 12	 and,	
under	 similar	 conditions,	 a	 94%	 yield	 of	 benzhydryl-protected	 analogue	 13	 (Scheme	 2).	 These	
compounds	 were	 obtained	 in	 high	 purity	 after	 a	 simple	 aqueous	 work-up	 and	 were	 indefinitely	
stable	to	room	temperature	storage.	Under	analogous	conditions,	three	additional	enamines	were	
prepared	 from	β-ketoester	 9	 using	 functionalised	 amines,	 all	 in	 excellent	 yields	 (Scheme	 S2,	 SI).	
Despite	having	efficient	access	 to	enamines	12	and	 13,	we	were,	however,	unable	 to	affect	 their	
reduction	 to	 the	 corresponding	 β-amino	 esters	 14	 under	 standard	 protocols	 (Scheme	 2),[27]	
resulting	in	decomposition	and/or	complex	mixtures	that	did	not	contain	the	desired	products	(for	
specific	 conditions	attempted,	 see	Table	S1,	 SI).	We	 thus	 turned	our	attention	 to	alkylation	of	β-
ketoesters	9	and	10	with	the	aim	of	preparing	C-3	fully-substituted	derivatives.	Although	this	would	
increase	 the	 steric	 encumbrance	 of	 the	 ketone,	 we	 envisioned	 that	 removing	 (enamine)	
conjugation	with	 the	 ester	would	 increase	 the	 reactivity	 of	 a	 derived	 imine	 towards	 protonation	
and	 reduction.	 Accordingly,	 3-methyl	 derivatives	 15	 and	 16	were	 prepared	 by	 treatment	 of	 β-
ketoester	9	 and	10	 with	 iodomethane	 in	 the	 presence	 of	 potassium	 carbonate	 (Scheme	 3).	 This	
alkylation	 showed	 reasonable	 diastereoselectivity	 (ca.	 7:1	 ratio	 of	 diastereomers	 after	 work-up)	
with	preference	for	methylation	trans	to	the	aryl	group.	In	both	cases	the	major	diastereomer	was	
efficiently	separated	from	the	minor	epimer	by	flash	chromatography	and	all	four	compounds	(15,	
16	and	epi-15/16	–	epimeric	at	C-3)	were	fully	characterised.	The	relative	stereochemistry	of	THF	16	
was	determined	at	this	stage	by	X-ray	crystallography.	
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Scheme	3.	Synthesis	of	β-amino	esters	19	and	20.	 [a]	 Isolated	dr	=	>20:1.	 [b]	 Isolated	dr	=	8:1.	 [c]	Excess	
CH(Ph)2NH2	was	recovered	as	the	hydrochloride	salt	(3.9	equiv	recovered	out	of	5.0	equiv	used).		
	
Ketones	15	and	16	proved	to	be	challenging	substrates	for	the	key	reductive	amination	step	and	most	
known	methods	attempted	were	unsuccessful	in	forming	the	desired	products	(e.g.,	
4-methoxybenzylamine	with	NaBH(OAc)3/1,2-dichloroethane[28],	benzhydrylamine	with	
NaBH4/trifluoroethanol[29]	or	NaBH4/Ti(Oi-Pr)4/THF[30]).	Ultimately,	by	heating	the	ketones	and	an	excess	of	
benzhydrylamine	(5	equiv)	in	methanol	under	acidic	conditions	with	sodium	cyanoborohydride	as	
reductant,	amines	17	and	18	were	obtained	in	acceptable	yields	of	48%	and	55%,	respectively	(Scheme	
3).[31]	The	excess	benzhydrylamine	could	be	conveniently	recovered	as	the	hydrochloride	salt	if	desired,	as	
demonstrated	in	the	former	case	(3.9	equiv	recovered).	Most	importantly,	this	amination	protocol	was	
amenable	to	multigram	scale	and	occurred	with	complete	diastereoselectivity	for	both	examples	to	give	the	
all-cis	relationship	between	the	three	contiguous	stereocentres.	In	order	to	avoid	potential	
chemoselectivity	issues	arising	from	the	embedded	benzylic	ether,	we	avoided	the	use	of	hydrogenolysis	or	
strongly	acidic	conditions	for	removal	of	the	benzhydryl	group.	Thus,	oxidative	removal	of	the	benzhydryl	
group	proceeded	smoothly	with	DDQ,[32]	providing	amines	19	and	20	in	83%	and	79%	yields,	respectively	
(Scheme	3).	 
With	gram	quantities	of	the	amino	esters	19	and	20	in	hand,	the	synthesis	of	our	first	set	of	core	
scaffolds	(represented	by	THF	4	in	Scheme	1)	was	undertaken.	Firstly,	the	divergent	preparation	of	
carboxylic	acids	was	examined	via	sequential	N-functionalisation	and	ester	saponification	(Scheme	
K2CO3, 
MeI
THF, rt
22-42 h
15: R1 = H       69%[a]  [+ epi-15: 5%[a]]
16: R1 = OMe  64%[a]  [+ epi-16: 7%[b]]
CH(Ph)2NH2 (5 equiv) 
NaBH3CN, AcOH 
3 Å MS, MeOH, 60 °C, 17 h
17: R1 = H       48%[a,c] (3.8 g)
18: R1 = OMe  55%[a]   (1.5 g)
DDQ, 4 Å MS, benzene 
60 °C, 1-2 h
then 1 M HClaq, MeOH
rt, 10-30 min
19: R1 = H       83%
20: R1 = OMe  79%
9 and 10
O
NH CO2Me
Me R1
O
H2N CO2Me
Me R1
Ph
Ph
O
CO2Me
Me R1
O
3
(X-ray crystal 
 structure of 16)
7	
4).	Thus,	amine	19	was	treated	with	methanesulfonyl	chloride	and	separately,	with	formaldehyde	in	
a	double	reductive	methylation,	giving	sulfonamide	21	and	tertiary	amine	22	in	77%	and	94%	yields,	
respectively.	 Subsequent	 saponification	 of	 the	 sterically	 hindered	 esters	 was	 not	 trivial,	 but	was	
achieved	with	excess	lithium	hydroxide	at	elevated	temperatures,	without	notable	decomposition.	
Under	these	conditions,	carboxylic	acid	23	was	obtained	in	96%	yield	after	heating	for	16.5	h.	Ester	
22	was	more	resilient	to	hydrolysis,	likely	due	to	inductive	carbonyl	deactivation	by	the	basic	amino	
group.	Nonetheless,	the	zwitterionic	amino	acid	24	was	isolated	in	good	yield	(80%)	after	prolonged	
heating.	
	
	
Scheme	4.	Synthesis	of	carboxylic	acids	23	and	24.	
	
To	retain	the	primary	amino	group	in	a	complementary	set	of	scaffolds,	amino	esters	19	and	20	
were	Boc-protected	 to	enable	manipulation	of	 the	ester	moiety	 (Scheme	5).	 Thus,	 the	protected	
derivatives	25	and	26	were	saponified	under	the	previously	developed	conditions	to	give	carboxylic	
acids	27	 and	28,	which	were	coupled	with	benzylamine	and	pyrrolidine	as	 representative	amines	
under	the	action	of	HATU.	Notably,	these	reactions	proceeded	at	room	temperature	and	afforded	
good‒excellent	 yields	 of	 amides	 29‒31,	 despite	 the	 sterically	 encumbered	 nature	 of	 the	 acid.	
Separately,	alcohol	32	was	produced	(79%	yield)	by	reduction	of	ester	25	with	lithium	borohydride.	
Deprotection	of	penultimate	 compounds	29‒32	with	TFA	proceeded	 smoothly	 in	 all	 cases,	 giving	
amines	33‒36	in	82‒96%	yields.	
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Scheme	5.	Synthesis	of	amines	33‒36.	[a]	The	azabenzotriazolyl	ester	was	also	isolated	in	7%	yield.	
	
As	discussed	earlier,	our	proposed	synthetic	approach	to	pyrrolidino-fused	analogues	8	relied	on	
the	previously	prepared	oxo-furans	(9	and	10)	as	common	precursors,	to	enable	annulation	of	the	
second	ring	via	intramolecular	reductive	amination	(Scheme	1).	To	build-in	the	required	tether,	C-3-
allylation	of	β-ketoesters	9	and	10	was	carried	out	with	allyl	bromide	under	analogous	conditions	to	
methylation	 (K2CO3,	THF,	Scheme	6).	Although	heating	was	 required	 to	ensure	adequate	 reaction	
rates,	the	desired	products	37	and	38	were	formed	in	good	yields	and	excellent	diastereoselectivity	
(dr	 =	 ≥20:1	 after	 work-up),	 with	 the	 same	 stereochemical	 preference	 as	 observed	 in	 the	
methylation,	as	confirmed	through	X-ray	crystal	structures	of	downstream	derivatives	47	(Scheme	
6)	 and	 58	 (Scheme	 8).	 Using	 these	 terminal	 alkenes	 (37	 and	 38),	 a	 one-pot	 tandem	
ozonolysis/double	reductive	amination	procedure	was	developed	using	4-methoxybenzylamine	and	
sodium	 cyanoborohydride	 as	 reductant,[33]	 enabling	 the	 preparation	 of	 multigram	 quantities	 of	
pyrrolidino-THFs	 39	 and	 40	 in	 rapid	 fashion	 with	 modest	 yields	 (55	 and	 59%).	 In	 this	 case,	 the	
requirement	for	a	cis-fused	pyrrolidine	ring	in	the	5,5-bicycle	overrides	the	previous	stereochemical	
preference	for	hydride	delivery	trans	to	the	ester	in	the	intermolecular	case	(see	amine	products	17	
and	18,	 Scheme	3).[34]	 The	 highly	 functionalised,	 stable	 aldehyde	41	 could	 also	 be	 isolated	 (79%)	
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after	 a	 modified	 reductive	 work-up	 with	 triphenylphosphine	 (see	 the	 SI),	 however,	 for	 our	
purposes,	the	one-pot	reductive	amination	method	proved	more	practical	and	gave	slightly	higher	
overall	yields	than	a	stepwise	procedure.		
	
	
	
Scheme	6.	Synthesis	of	pyrrolidino-THFs.	 [a]	Product	dr	(before	and	after	chromatographic	purification)	=	
≥20:1.	[b]	Depicted	as	the	opposite	enantiomer	to	drawn.	
	
The	embedded	functional	array	in	the	bicyclic	products	was,	by	design,	analogous	to	the	original	
THF	 scaffolds,	 allowing	 further	manipulations	 to	 be	 performed	 in	 a	 similar	manner	 to	 previously	
described	as	outlined	in	Schemes	6	and	7.	The	ester	was	hydrolysed	to	zwitterionic	amino	acids	42	
and	43,	which	were	isolated	in	88%	and	74%	yields,	respectively,	after	precipitation	from	water	at	
pH	 5	 (Scheme	 6).	 Alternatively,	 exchange	 of	 the	 para-methoxybenzyl	 (PMB)	 group	with	 the	 Boc	
group[35]	 using	 1-chloroethyl	 chloroformate,[36]	 allowed	preparation	of	 Boc-protected	 amino	 acids	
46	and	47	(Scheme	6),	which	were	readily	amenable	to	amide	coupling	reactions	or	reduction	with	
lithium	 borohydride	 (Scheme	 7).	 The	 obtained	 amides	 48‒50	 and	 alcohol	 51	 were	 cleanly	
deprotected	with	 TFA	 to	 give	 an	 additional	 set	 of	 scaffolds	52‒55	with	 an	 unmasked	 pyrrolidine	
nitrogen	(Scheme	7).	
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(X-ray crystal structure of 47)[b]
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Scheme	7.	Synthesis	of	amines	52‒55.	
	
The	 relative	orientation	of	 the	 three	 stereocentres	 in	 the	monocyclic	 and	bicyclic	 THF	 scaffolds	
was	confirmed	through	X-ray	crystal	structures	of	derivatives	56‒58,	prepared	via	N-sulfonylation,	
aryl	 bromination	 and	N-acylation,	 respectively	 (Scheme	 8).	 Notably,	 the	 cis-relationship	 between	
the	amino	group	and	 the	amide	 in	 the	monocyclic	 THF	 system	 (i.e.,	56	 and	57)	 compared	 to	 the	
trans-arrangement	 in	 the	 bicyclic	 scaffold	 (58),	 allows	 the	 occupation	 of	 distinct	 chemical	 space	
from	the	N-substituent	between	the	two	systems.	Further,	the	facile,	regioselective	bromination[37]	
of	THF	30	 demonstrates	 the	potential	of	 the	methoxy	group	 to	enable	 chemoselective	 late-stage	
functionalisation	of	 the	 aryl	 ring,	 as	mentioned	earlier.	 This	 halogen	 could	potentially	 be	used	 in	
future	 studies	 as	 a	 handle	 to	 explore	 an	 additional	 vector	 proximal	 to	 the	 THF	 core	 via	 cross-
coupling	reactions.		
amine, NEt(i-Pr)2
HATU, DMF
0 °C-rt, 24-34 h
50: 96%48: R1 = H       93%
49: R1 = OMe  85%
(amine = 
  pyrrolidine)
  (46 only)
(amine = 
BnNH2)
O
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H
R1
NHBn
O
O
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H
N
O
46 and 47
Ph
46
52: R1 = H       86%
53: R1 = OMe  98%
TFA, CH2Cl2
rt, 6.5-7 h
TFA, CH2Cl2
rt, 7 h
54: 70%O
HN
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NHBn
O O
HN
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O
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LiBH4, MeOH
THF, 50 °C,
23 h
51: 89%
O
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H
OH
Ph
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55: 88%
O
HN
H
OH
Ph
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Scheme	8.	Synthesis	and	X-ray	crystal	structures	of	derivatives	56‒58.	[a]	The	X-ray	crystal	structure	of	56	is	
depicted	as	the	opposite	enantiomer	to	drawn.	
	
The	chemical	space	distribution	of	the	12	prepared	THF	scaffolds	relative	to	molecular	weight	and	
AlogP	was	 formulated	using	 the	computational	model	LLAMA[21]	 (Figure	2;	physical	properties	 for	
each	compound	are	fully	documented	in	Table	S2,	SI).	Each	of	these	core	scaffolds	retains	either	a	
nucleophilic	amino	group	or	a	carboxylic	acid	functionality,	offering	potential	to	create	compound	
libraries	 through	 further	 derivatisation.	As	 shown	 in	 Figure	 2,	 all	 examples	 fall	within	 or	 close	 to	
lead-like	 territory[18]	 (molecular	 weight	 <350,	 AlogP	 <3),	 enabling	 significant	 flexibility	 for	
derivatisation	within	Lipinski	space	(molecular	weight	<500,	AlogP	<5).	A	balanced	pharmacokinetic	
profile	is	predicted	by	an	average	AlogP	of	1.7	and	topological	polar	surface	area	(TPSA)	of	59.3	Å2	
(Table	 S2,	 SI),	 suggesting	 good	 oral	 bioavailability[38]	 while	 preserving	 capacity	 to	 penetrate	 cell	
membranes,	including	the	blood-brain	barrier	for	central	nervous	system	(CNS)	targets.[39]		
	
ArSO2Cl
pyridine
CH2Cl2
rt, 18 h
70% O
NH
Ph
Me
NHBn
O
SBr
O
O
NBS, MeCN
rt, 16 h
O
BocHN
OMeMe
O
NHBn
Br
94%
cyclopropane-
carboxylic acid
NEt(i-Pr)2, HATU
DMF, rt, 16 h
62%
33
56[a]
30
57
52
O
N
H
O
O
NHBn
58
Ph
12	
	
Figure	 2.	 Chemical	 space	 distribution	 of	 the	 prepared	 scaffolds	 relative	 to	molecular	 weight	 and	 AlogP,	
generated	using	LLAMA.[21]	Data	points	are	labelled	with	the	corresponding	compound	numbers.		
	
The	principal	moments	of	 inertia	 (PMI)[40]	 plot	of	 the	12	 compounds	 (Figure	3,	 generated	using	
LLAMA[21])	 shows	 a	 good	 degree	 of	 shape	 coverage	with	 reasonable	 spherical	 character,	moving	
away	from	the	predominant	rod-	or	disc-like	character	observed	in	commercial	fragment	libraries[41]	
and	known	bioactive	compounds.[42]	The	three-dimensional	nature	of	the	THF	scaffolds[43]	is	further	
supported	by	an	average	plane-of-best-fit	(PBF)[44]	deviation	of	1.0	Å	(Table	S2,	SI),	which	compares	
favourably	with	that	of	the	ChEMBL	database[45]	of	published	bioactive	compounds	(average	PBF	for	
ChEMBL	compounds	=	0.6	Å).[42]	
	
13	
	
Figure	3.	Principal	moments	of	inertia	(PMI)	plot	of	the	prepared	scaffolds,	generated	using	LLAMA.[21]	Data	
points	are	labelled	with	the	corresponding	compound	numbers.		
	
To	demonstrate	the	ability	to	derivatise	these	THF	scaffolds,	a	small	library	of	24	compounds	(59‒
82)	 was	 prepared	 and	 fully	 characterised	 (Figure	 4;	 full	 details	 are	 given	 in	 the	 SI).	 Standard	
transformations	 were	 utilised	 including	 N-acylation,	 N-reductive	 alkylation,	 N-sulfonylation	 and	
carboxylic	 acid-amide	 couplings.	 Outside	 of	 this	 compound	 set	 (Figure	 4),	 an	 additional	 1948	
compounds	 were	 prepared	 and	 submitted	 to	 the	 Joint	 European	 Compound	 Library	 (JECL),[46]	
consisting	of	923	derivatives	of	4	with	an	average	molecular	weight	of	403	and	an	average	clogP	of	
2.0	and	1025	derivatives	of	8	with	an	average	molecular	weight	of	448	and	an	average	clogP	of	2.5	
(see	the	SI	 for	 further	details).	These	compounds	are	 freely	available	 for	 target	screening	to	both	
academic	and	private	researchers	through	the	ELF	initiative.[14]		
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Figure	4.	Representative	synthetic	 library	prepared	from	the	amine	and	carboxylic	acid	THF	scaffolds.	See	
the	SI	for	full	details.	
	
Conclusions	
A	 series	 of	 highly	 substituted	 THFs	 and	 pyrrolidino-THFs	 embedded	 with	 modifiable	 2-aryl,	 3-
carboxy	and	4-amino	functionalities	has	been	prepared.	Divergent	synthetic	routes	were	developed	
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to	 access	 the	 desired	mono-	 and	 bicyclic	 scaffolds	 via	 a	 common	 4-oxofuran	 intermediate,	 from	
which	 inter-	 and	 intramolecular	 reductive	 aminations,	 respectively,	 enabled	 diastereoselective	
formation	 of	 the	 key	 C-4‒N	 bond.	 These	 scaffolds	 were	 designed	 with	 careful	 consideration	 of	
novelty,	stereochemical	complexity,	synthetic	tractability	and	diversity	potential,	and	show	promise	
in	drug	discovery,	as	demonstrated	by	their	desirable	physical	properties	and	ease	of	elaboration	to	
diverse	compound	libraries.	
	
Experimental	Section	
Full	experimental	details	are	given	in	the	SI.	
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